Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting

Alifya Lokhandwala, Cilomar Martins de Oliveira Filho, Philip Amrein, Amir Fathi, Gabriela Hobbs, Hanno Hock, Rupa Narayan, Andrew Brunner, Michelle Lee

Blood (2025) 146 (Supplement 1): 8171.

https://doi.org/10.1182/blood-2025-8171

Published: 2025

Journal Articles

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Andrew M. Brunner, Yiwen Liu, Rupa Narayan, Michelle Hyunju Lee, Philip C. Amrein, Hanno Hock, Gabriela S. Hobbs, Donna S. Neuberg, Timothy Aaron Graubert, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2024-196718

Published: 2024

Journal Articles

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Rupa Narayan, Ronan T. Swords, Philip C. Amrein, Andrew M. Brunner, Gabriela S. Hobbs, Hanno Hock, Michelle Hyunju Lee, Timothy Aaron Graubert, Amir T. Fathi, Robert P Hasserjian, Valentina Nardi

Blood (2024) 144 (Supplement 1): 6154.

https://doi.org/10.1182/blood-2024-211201

Published: 2024

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Roxana A Portillo, Michelle Hyunju Lee, Harrison K. Tsai, Daniel J DeAngelo, Amir T. Fathi, Rupa Narayan, Marlise R Luskin, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6598.

https://doi.org/10.1182/blood-2024-206655

Published: 2024

Journal Articles

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

Jessica Freydman, David Sirignano, Philip C. Amrein, Meghan Bergeron, Andrew M. Brunner, Elsie Foster, Amir T. Fathi, Timothy Aaron Graubert, Hanno Hock, Michelle Hyunju Lee, Jenna Moran, Rupa Narayan, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6591.

https://doi.org/10.1182/blood-2024-203629

Published: 2024

Journal Articles

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andrew M. Brunner, Yiwen Liu, Jacqueline S. Garcia, Lourdes Mendez, Catherine Gutierrez, Philip C. Amrein, Rupa Narayan, Rahul Vedula, Donna S. Neuberg, Marcio Andrade-Campos, Simon Smith, Richard M Stone, Amir T. Fathi, Matthew J. Walter, Timothy Aaron Graubert, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2024-195793

Published: 2024

Journal Articles

Changes in White Blood Cell Counts Early during Treatment of Acute Leukemia Using Differentiating Chemotherapies

Amyah C. Harris, Christopher S. Bell, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Rupa Narayan, Amir T. Fathi, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2023-187367

Published: 2023

Journal Articles

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

Aonkon Dey, Rupa Narayan, Neal Smith, Alice Tirard, Benjamin Arnold, John McGuire, Thomas Chan, Jennifer Lombardi Story, Timothy Casson, Tanya Toni Behnan, Amir T. Fathi, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Patrick Reeves, Timothy Aaron Graubert, Andrew M. Brunner, Alexandra-Chloé Villani

Blood (2023) 142 (Supplement 1): 4319.

https://doi.org/10.1182/blood-2023-189858

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

Journal Articles

Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia

Priyanka Pullarkat, Yael Flamand, Harish Seethapathy, Meghan Sise, Andrew M. Brunner, Amir T. Fathi, Rupa Narayan

Blood (2023) 142 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2023-191110

Published: 2023

Journal Articles

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Manik Razdan Kuchroo, Robert A. Redd, Jacqueline S. Garcia, Michael Keng, Gabriela S. Hobbs, Jacalyn Rosenblatt, Marlise R. Luskin, Rupa Narayan, Philip C. Amrein, Malgorzata McMasters, Martha Wadleigh, Hanno Hock, Richard Stone, Donna S. Neuberg, David Avigan, Karen K. Ballen, Amir T. Fathi, Daniel J. DeAngelo, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2023-188182

Published: 2023

Journal Articles

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss

Blood (2022) 140 (Supplement 1): 3284–3286.

https://doi.org/10.1182/blood-2022-162525

Published: 2022

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2022) 140 (Supplement 1): 3309–3311.

https://doi.org/10.1182/blood-2022-160100

Published: 2022

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Blood (2021) 138 (Supplement 1): 244.

https://doi.org/10.1182/blood-2021-146039

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate

Blood (2021) 138 (Supplement 1): 3677.

https://doi.org/10.1182/blood-2021-151455

Published: 2021

Journal Articles

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Chi-Joan How, MD, Siyang Ren, Jennifer Lombardi Story, Meghan Bergeron, NP, Julia E. Foster, NP, Philip C. Amrein, MD, Andrew M. Brunner, Amir T. Fathi, Hanno R. Hock, MD PhD, Jenna A. Moran, NP, Rupa Narayan, Donna S. Neuberg, ScD, Aura Y. Ramos, RN, Tina T. Som, RN, Megan Vartanian, RN, Yi-Bin Chen, MD, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140278

Published: 2020

Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137307

Published: 2020

Journal Articles

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140176

Published: 2020

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136855

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Changes in White Blood Cell Counts Early during Treatment of Acute Leukemia Using Differentiating Chemotherapies

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only